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Running title: 
Cholestyramine Protects Dried Lactobacillus Casei from Bile 
ABSTRACT 
Enteric coated oral tablets or capsules can deliver dried live cells directly into the intestine. 
Previously, we found that a live attenuated bacterial vaccine acquired sensitivity to intestinal bile 
when dried, raising the possibility that although gastric acid can be bypassed, significant loss of 
viability might occur on release from an enteric coated oral formulations. Here we demonstrate 
that some food-grade lyophilised preparations of Lactobacillus casei and Lactobacillus salivarius 
also show temporary bile sensitivity that can be rapidly reversed by rehydration. To protect dried 
cells from temporary bile sensitivity, we propose using bile acid adsorbing resins, such as 
cholestyramine, which are bile acid binding agents, historically used to lower cholesterol levels. 
Vcaps™ HPMC capsules alone provided up to 830-fold protection from bile. The inclusion of 
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50% w/w cholestyramine in Vcaps
TM
 HPMC capsules resulted in release of up to 1700-fold more 
live Lactobacillus casei into simulated intestinal fluid containing 1% bile, when compared to 
dried cells added directly to bile. We conclude that delivery of dried live probiotic organisms to 
the intestine may be improved by providing protection from bile by addition of bile adsorbing 
resins and the use of HPMC capsules. 
 
Highlights 
-When dispersed in bile at intestinal concentrations some dried probiotic bacteria are killed 
-Bile toxicity can be blocked using the bile adsorbing resin cholestyramine 
-Formulation with bile adsorbants may protect dried probiotic bacteria from intestinal bile 
-Some hard shell capsules can alone provide protection from bile 
KEYWORDS  
Probiotic bacteria, bile adsorbing resin, cholestyramine, bile, oral delivery 
ABBREVIATIONS 
BAR, bile acid adsorbing resin. LAB, lactic acid bacteria. LBV, live bacterial vaccine. HPMC, 
hydroxyl methyl cellulose. 
 
Introduction 
Live bacteria are administered orally for a range of therapeutic applications, ranging from 
live oral attenuated enteric pathogens used as vaccines to commensal bacteria administered in 
foods such as yoghurt. Therapeutic live bacteria represent a major delivery challenge for 
pharmaceutical scientists, presenting problems with maintaining viability during manufacture and 
storage, as well as difficulty in producing oral formulations due to sensitivity to moisture, 
temperature and pressure. Once an oral formulationcontaining live stabilised bacteria has been 
manufactured, there remains one final major delivery challenge: to maintain bacterial viability 
after oral administration and survive the harsh microbicidal conditions encountered in the 
gastrointestinal tract. 
A wide range of live microbes, termed probiotics, have been proposed to confer a broad 
range of therapeutic benefits when administered orally. These benefits range from re-colonisation 
of the gut after antibiotic treatment to reduce the severity of diarrhoea [1], beneficial modification 
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of gut metabolism [2], suppression of intestinal inflammation [3], and when genetically modified, 
for delivery of biopharmaceuticals in situ [4]. Although many formulations have been developed 
for oral delivery of live bacteria ranging from exotic functional foods such as confectionary to 
traditional dairy products such as yoghurt [5], solid dosage forms such as capsules or tablets 
containing dried live probiotic bacteria offer the most control of both dose and site of delivery 
and drying also increases shelf life and stability. 
For effective function, it is essential for live organisms to overcome the highly efficient 
microbicidal barriers present in the human gastrointestinal tract. Gastric acid, which is sterilising 
to all but the most robust microbe, can be avoided by coating the dose with acid-insoluble enteric 
polymers. However, dried live probiotic cells released from enteric coated oral doses are then 
exposed to intestinal bile acids, the major component of bile secreted from the gall bladder. 
Although the main function of bile acids is as a detergent to solubilise dietary lipids, many 
microbes are intolerant of detergents and bile represents a major microbicidal barrier to survival 
of probiotic bacteria [6]. Indeed, bile tolerance is a major factor considered when bacterial strains 
are selected as candidate probiotics [7].  
An additional challenge is faced when live bacteria are dried, because cell injury caused 
during drying can increase the sensitivity of bacteria to microbicides; for example transient cell 
wall damage can occur after freezing which allows detergents such as bile acids to kill cells [8]. 
We found that even a highly bile resistant live attenuated bacterial vaccine (LBV) strain of 
Salmonella typhimurium became sensitive to moderate bile concentrations [9]. The degree of bile 
sensitivity observed for dried cells depends on a number of factors including the culture 
conditions and growth stage prior to drying, and on the drying method and excipient used ([9] and 
unpublished observations). Importantly, with highly bile adapted enteric organisms such as 
Salmonella, this temporary bile sensitivity is reversed very rapidly – i.e. within minutes – after 
rehydration [8, 10]. Having discovered this temporary increased sensitivity of LBV to bile after 
drying, we developed a simple formulation that protects transiently bile sensitive dried LBV by 
temporary bile acid adsorption using bile acid adsorbing resins (BAR) [9-11].  
In the current study we ask two further questions. Firstly, is drying-induced temporary 
bile senstivity restricted to LBV dried in the laboratory, or do dried lactic acid bacteria (LAB) 
produced as human food supplements also exhibit increased bile sensitivity after drying? 
Secondly, is it possible that BAR can be utilised to protect dried LAB from bile in a simple oral 
formulation suitable for delivery of probiotics? 
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Materials and Methods 
 MRS agar, dried pig and ox bile, cholestyramine, and microcrystalline cellulose (MCC, 
Avicel PH 101) were obtained from Sigma Aldrich (Dorset, UK). Simulated intestinal fluid was 
Phosphate Standard Buffer specified by the International Pharmacopeia as 0.025M potassium 
dihydrogen phosphate and 0.025M di-sodium hydrogen phosphate at pH6.8, and where indicated 
dried pig or ox bile was dissolved followed by filtration. Capsules were size 00 Vcaps™ HPMC 
capsules supplied by Capsugel (Bornhem Belgium). Powders containing the lactic acid bacteria 
Lactobacillus casei strain UALC-03; Lactobacillus acidophilus strain DDS-1; Lactobacillus 
salivarius strain UALS-07 were commercially manufactured through a fermentation process and 
freeze-drying by UAS labs (Minnesota, USA). Strain identity was confirmed and powders 
screened for pathogens by the manufacturer; the powder was supplied as a food supplement 
suitable for human consumption.  
To test the bile sensitivity of dried and rehydrated bacteria, individually weighed samples 
were placed in 50ml test tubes, and 25ml of simulated intestinal fluid with or without 1% pig bile 
were added, followed by incubation at 37ºC and sampling live cell numbers at 1 and 2 hours. In 
some cases, the LAB powder was firstly rehydrated in 12.5ml simulated intestinal fluid without 
bile for 1h, followed by dilution with 12.5ml 2% pig bile, such that the final bile concentration 
was identical to the sample directly exposed to bile. 
To test protection provided by different formulations against bile toxicity, L. casei 
powder was mixed either with MCC filler alone or a mixture of MCC and cholestyramine, and 
size 00 Vcaps™ HPMC capsules (Capsugel, Bornem Belgium) were filled with approximately 
300mg powder, of which 13-15% w/w of capsule content was L. casei powder corresponding to 
39-45mg per capsule, and 50% w/w was cholestyramine (where added). Capsules were filled by 
hand using a Cap-M-Quick (Value Healthcare, Rotherham, UK), and fitted into a wire sinker. 
Individual capsules were weighed and added to 50ml tubes containing 25ml of simulated 
intestinal fluid alone or with the indicated concentrations of ox or pig bile, and incubated for 1h at 
37ºC, followed by sampling to determine live cell numbers. 
To measure live cell numbers, cells and residual excipients were thoroughly resuspended, 
samples were taken at the stated times and serially 4-fold diluted in phosphate buffer in sterile 96-
well microwell plates. Replicate 10ul portions of the diluted cells were plated as spots on MRS 
agar, followed by incubation at 37ºC for 48-72h. Colony forming units (CFU) were counted, and 
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the equivalent viable cell recovery per weight of initial LAB powder was then calculated based 
on the dilution and volumes used. 
Results 
Transient bile sensitivity in lyophilised LAB powders 
Initial experiments focussed on determining if commercially manufactured, food grade 
dried LAB display the same temporary increased bile sensitivity seen when LBV were dried in 
the laboratory. Samples of lyophilised powders of a range of different LAB were tested by 
comparing viable cell recovery in three conditions: after rehydration in buffer for 1 and 2h; after 
direct exposure to a 1% ox bile solution for 1 and 2h; and finally after rehydration and recovery 
for 1h in buffer, followed by switching to a 1% ox bile solution for a further 1h incubation.  
Two distinct patterns of viable cell recovery were observed, depending on the LAB 
powder tested. In some cases, illustrated here by preparations of L. casei  and L. salivarius, dried 
cells were more bile sensitive than after rehydration. Direct exposure to bile gave very high loss 
of viability, but far lower losses were found when rehydrated in buffer followed by bile exposure. 
When directly exposed to 1% bile, a preparation of L. casei showed 10
3
 –fold loss at 1h, and L. 
salivarius showed >10
5
-fold loss by 1h, compared to dissolution in buffer alone. In contrast, 
when these preparations were first rehydrated for 1h in buffer followed by 1h exposure to bile, 
less than 100-fold loss of viable cell recovery was observed (Fig. 1). 
With other dried LAB powders, illustrated here by a preparation of L. acidophilus, no 
difference in bile sensitivity was seen regardless of whether the powder was directly exposed to 
bile or rehydrated first, suggesting these particular strains or preparations may have intrinsic – 
rather than drying-induced – bile sensitivity (Fig. 1). With the preparation of L. acidophilus, little 
toxicity was seen after 1h exposure to bile, and approximately 100-fold loss of viability was seen 
after either 2h exposure bile or buffer followed by bile (Fig. 1). 
 
Protection from bile toxicity using BAR in capsules 
To overcome temporary bile toxicity, a bile binding agent such as the BAR 
cholestyramine can simply be mixed with dried LBV to temporarily adsorb bile acids and allow 
bile resistance to recover [10, 11]. Furthermore, capsules made from hydroxymethylpropyl 
cellulose (HPMC), a vegetarian alternative to hard gelatine shells, can confer a significant degree 
of bile protection to dried LBV without addition of BAR [11]. We tested if Vcaps™ HPMC 
capsules alone, or an optimised formulation with cholestyramine Vcaps™ HPMC capsules could 
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also confer protection from bile to dried LAB. Two concentrations of ox bile and pig bile were 
compared, since differences in bile acid composition can affect toxicity [6]. 
When L. casei powder was mixed with filler alone and filled into Vcaps™ HPMC 
capsules, dissolution in bile solutions resulted in a dose-dependent loss in viable cell recovery 
after 1h incubation (Fig. 2). The bile toxicity seen with L. casei filled in Vcaps™ HPMC capsules 
(Fig. 2) was significantly lower than that observed when L. casei powder was exposed directly to 
1% pig-bile (Fig. 1), suggesting that capsules alone provide some protection from bile. However, 
when the BAR cholestyramine was included within the capsule, minimal reduction in live cell 
recovery was seen at all concentrations of bile tested. This demonstrates that formulation of dried 
LAB with BAR in capsules effectively protects cells from temporary bile toxicity, as found 
previously with LBV.  
Discussion 
Four methods have previously been explored for protecting beneficial probiotic bacteria 
from bile toxicity after oral administration. Firstly, probiotic strains can be selected for increased 
bile resistance [7]. Secondly, bacteria can be adapted by culture conditioning for example by 
addition of detergents to media during fermentation, resulting in increased bile resistance [12, 
13]. Thirdly, a wide range of microencapsulation technologies have been developed to produce 
micro formulated probiotic preparations with increased acid and bile sensitivity [2, 14]. Lastly, 
for advanced therapies using engineered strains to produce biopharmaceuticals in situ in the gut, 
genetic modification to confer increased bile resistance has been explored [15, 16]. 
We propose a new, simpler method, specifically for situations where increased toxicity is 
seen for dried probiotic powder when compared to previously hydrated cells in liquid culture. A 
simple oral dose form, such as a capsule, is filled with a BAR such as cholestyramine mixed with 
dried probiotic cells and enteric coated to provide protection from gastric acid; this coating 
dissolves as the pH rises in the duodenum, resulting in release of dried cells directly into the 
upper small intestine. When the enteric coating is dissolved and the capsule contents hydrated by 
intestinal fluids, bile acids are temporarily bound by BAR, and the dried bacteria are rehydrated 
giving time for recovery of bile resistance. Since cholestyramine is manufactured as a generic on 
a large scale, and has a long history of safe use, their inclusion as an additional excipient should 
not significantly add to the cost or ease of regulatory approval of an oral probiotic medicine. 
In this simple in vitro study, 1h incubation of dried L. casei powder in 1% pig bile 
released 3,500-fold fewer live cells than buffer alone (Fig. 1); in contrast when the same powder 
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was filled into capsules with cholestyramine, only 2-fold fewer live cells were recovered (Fig. 2), 
representing a 1700-fold protection from bile. Note that the protection seen by inclusion of BAR 
within HPMC capsules cannot simply be accounted for by bulk depletion of the solution of bile 
acids. 150mg of cholestyramine has a capacity to bind a maximum of 570µmole bile acids [17], 
yet 25ml 4% bile solution contains 2500µmole bile acids. Therefore protection is provided 
against >4-fold excess of bile acids. We proposed a mechanism for protection that suggests that 
temporary depletion of bile acids occurs in the hydrating oral dose form containing BAR [11]. 
The dried bacteria rehydrate and recover bile resistance, followed by release into the bulk bile 
solution. 
Surprisingly, Vcaps™ HPMC capsules alone provide significant protection of dried LAB 
from bile, when compared to dispersing powder directly into bile solutions (Figs. 1 and 2). 
Previously, we found that depending on the capsule shell material, simply filling dried LBV 
powder into capsules prior to exposure to bile solutions give significant protection from bile 
toxicity compared to powder dispersed directly into bile, with Vcaps™ HPMC capsules giving 
the best protection and alone able to confer 860-fold protection from 1% bile for dried S. 
typhimurium [11]. We suggested this might be due to the capsule shell material forming a gel that 
retards bile acid entry and protects cells during dissolution: different shell polymers have varying 
intrinsic gel stability and bile acid binding potential, hence the variation in protection afforded by 
different capsule types. This protection was also observed with L. casei powder, with 830-fold 
protection from bile provided by Vcaps™ HPMC capsules alone (Figs. 1 and 2). In spite of this 
capsule-intrinsic protection, the best protection was afforded by inclusion of BAR, which gave an 
additional 3.1-fold protection over capsules alone (Fig. 2). 
This initial study suggests that the inclusion of BAR and use of HPMC capsules, in 
addition to enteric coating, offer possible benefits for delivery of dried LAB as therapeutic 
probiotics. Further research is needed to understand why some, but not all, food grade dried LAB 
preparations show temporary bile sensitivity. The formulation can be further tested in advanced in 
vitro gut models to confirm that the improved viability seen here in bile solutions is replicated in 
more accurately simulated intestinal conditions. In vivo delivery studies in suitable animal models 
such as pigs (large monogastric mammal with similar gastrointestinal conditions to humans) are 
also required to test if the improved viability in in vitro simulated intestinal conditions translates 
into an increase in live bacterial cell delivery to the intestine. Ulitmately clinical studies are vital 
to determine if improving delivery efficacy using advanced formulations of live bacteria can 
deliver therapeutic benefits. 
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FIGURE CAPTIONS 
Figure 1. Bile sensitivity of dried and rehydrated lactobacillus preparations. The bile sensitivity 
of different preparations of dried LAB was measured either when exposed to bile solutions 
directly as a dried powder or after hydration for 1h in phosphate buffer. Bars indicate the mean of 
4-6 replicate samples and error bars indicate 1 standard deviation. Similar bile sensitivity was 
observed in at least 2 replicate experiments with each probiotic preparation. 
Figure 2. Protecting dried L. casei from transient bile sensitivity using the BAR cholestyramine. 
Dried LAB powders were either filled into Vcaps™ HPMC capsules alone or with 
cholestyramine, and capsules added to buffer or bile solutions for 1h, followed by live cell 
determination. Bars indicate the mean of 4-6 replicate samples and error bars indicate 1 standard 
deviation. Similar results were obtained in at least 2 replicate experiments. 
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